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cetylation of lysine side chains in proteins is a re-
versible post-translational modification that occurs
in a wide range of organisms.1 This modification
affects the properties of proteins, including
protein–protein association, protein–DNA interac-
tions, and protein stability.2 Initially, acetylation gained
recognition as a post-translational modification to histones.
Acetylation of histones can regulate the accessibility of DNA
to cellular machinery and thus change the protein expression
profiles of cells.3 Because of the effect of acetylation on the
proteome, it is not surprising that many diseases have been
associated with the aberrant acetylation of histones.4 In the
last 12 years, the paradigm for protein acetylation has
changed drastically, moving from a histone centric model to
a proteome centric model. This change in mindset has
resulted from the identification of acetylated lysine side
chains that affect the function of numerous nonhistone
proteins.5,6 Currently, over 3600 acetylation sites have been
discovered in mammalian proteins,7 and these proteins are
important in many cellular processes, including gluconeo-
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The lysine deacetylase family of enzymes (HDACs) was
first demonstrated to catalyze deacetylation of acetyllysine
residues on histones. In subsequent years, HDACs have
been shown to recognize a large pool of acetylated
nonhistone proteins as substrates. Recently, thousands of
acetylated proteins have been discovered, yet in most
cases, the HDAC that catalyzes deacetylation in vivo has
not been identified. This gap has created the need for
better in vivo, in vitro, and in silico approaches for
determining HDAC substrates. While HDAC8 is the best
kinetically and structurally characterized HDAC, few
efficient substrates have yet been substantiated in vivo. In
this review, we delineate factors that may be important
for determining HDAC8 substrate recognition and
catalytic activity, including structure, complex formation,
and post-translational modifications. This summary
provides insight into the challenges of identifying in vivo
substrates for HDAC8, and provides a good vantage
point for understanding the variables important for
predicting HDAC substrate recognition. # 2012 Wiley
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genesis and DNA damage repair.5,6 Regulation of the acetyla-
tion state of proteins is important as aberrant acetylation of
both histone and nonhistone proteins can contribute to the
development of many disease states.8–10 As proof of this, two
broad spectrum lysine deacetylase/histone deacetylase
(HDAC) inhibitors [suberoylanilide hydroxamic acid
(SAHA) and Romidepsin] have been approved by the U.S.
Food and Drug Administration and are currently on the
market for the treatment of T-cell lymphomas (Figure 1).19
HDAC isozymes can be grouped into four classes based on
their phylogenetic similarity.20 Class I (HDAC1, 2, 3, and 8),
class IIa (HDAC4, 5, 7, and 9), class IIb (HDAC6 and 10), and
class IV (HDAC11) enzymes catalyze deacetylation using a
metal-dependent mechanism,20,21 while class III (Sirt1-7)
enzymes use an NAD1 cofactor to perform deacetylation.22,23
Because of the abundance and importance of HDAC sub-
strates, one of the foremost questions in the field is the deter-
mination of the substrate specificity of HDACs. This area of
research seeks to identify which of the 18 deacetylases catalyzes
deacetylation of each of the [3600 mammalian acetylation
sites. Adding to the complexity of this problem is the possibil-
ity that cellular regulation may alter both the catalytic activity
and the substrate specificity of HDACs. Illuminating the sub-
strate selectivity and regulation of HDACs should shed light on
the mechanism and treatment of acetylation-related diseases.
Mechanistically and structurally, HDAC8 is the best studied
of the HDAC homologs. Furthermore, HDAC8 is proposed to
recognize a number of nonhistone substrates24–26 and is there-
fore a good model for developing techniques to unravel HDAC
substrate specificity. In this review, we discuss the current view of
HDAC8 regulation and compare HDAC8 to other promiscuous
enzymes to identify factors that determine substrate specificity.
KNOWN HDAC8 SUBSTRATES
HDAC8was initially discovered in 2000 and was shown to cata-
lyze in vitro deacetylation of a number of acetylated histone var-
iants.27–29 These substrates included full-length H2A/H2B, H3,
and H4 histones acetylated at nonspecific lysines.27,28 Concur-
rent studies showed that peptide sequences corresponding to
the H4 histone tail with an acetylated lysine at position sixteen
[K(ac)16] were also in vitro substrates.28,29 In subsequent years,
several studies have used the H4 histone tail sequence as a pep-
tide template to investigate the amino acid sequence preference
of HDAC8 (discussed below).30–32 Recently, HDAC8 was dem-
onstrated to catalyze in vitro deacetylation of the K(ac)20 site
on the H4 histone tail. However, HDAC8-catalyzed deacetyla-
tion of the K(ac)20 peptide is much slower than deacetylation
of K(ac)16 peptides,33 suggesting that another HDAC isozyme
may catalyze this reaction in vivo. Despite these findings, the
role of HDAC8 in catalyzing deacetylation of specific sites in
histones in vivo remains unclear.
Shortly after HDAC8 was identified, the first nonhistone
acetylated proteins were reported,34,35 which inspired
FIGURE 1 Widely used HDAC inhibitors. SAHA and Romidepsin have been approved by the U.S.
Food andDrug Administration for use as second line treatments for T-cell lymphomas. TSA is an inhibi-
tor that has been used widely in in vitro and in vivo studies but is not being tested in drug trials.11 All
three inhibitors are competitive with substrates by occupying the substrate binding channel and coordi-
nating the active sitemetal ion. The atoms colored red interact with the active site metal ion.12–18
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researchers to hunt for other possible HDAC substrates. The
search for new HDAC8 substrates was further spurred by the
finding that this enzyme is present in the cytoplasm of
smooth muscle cells,36,37 causing evaluation of non-nuclear
substrates. In fact, HDAC8 catalyzes deacetylation of a
peptide corresponding to the C-terminal end of the p53
transcription factor (Figure 2a) faster than the K(ac)16 H4
histone peptide (Biomol, unpublished). HDAC8 catalyzes
deacetylation of coumarin derivatives of the acetylated p53
and H4 peptides with kcat/KM values of 7500 M
21s21 and
2800 M21s21, respectively.26,39 As the kcat/KM parameter
reflects the relative reactivity of an enzyme with different
substrates,40 these values suggest that HDAC8 has a modest
preference for catalyzing deacetylation of p53 over the H4
histone. It is important to note that these kcat/KM values for
HDAC8 were measured using the commercially available
Fluor-de-lys assay (Biomol). This assay uses peptide sub-
strates containing a methylcoumarin fluorophore conjugated
to the C-terminal side of the acetyllysine residue. After
deacetylation, digestion by trypsin cleaves the coumarin
fluorophore, causing an increase in fluorescence at 460 nm;
deacetylation is measured from an increase in the fluores-
cence signal38 (Figure 2b). While this assay has been a valua-
ble tool for studying histone deacetylases, the methylcou-
marin fluorophore increases the reactivity with HDAC8.41
Therefore, deacetylation of the nonlabeled acetylated p53
and H4 histone peptides catalyzed by HDAC8 may be slower
than reported using this assay. Furthermore, the coumarin
substrates may not reliably reflect HDAC substrate specificity
in the context of full-length proteins.
The steady-state kinetic parameters for catalysis of the
deacetylation of peptides can provide insight into both the
kinetic mechanism and the in vivo reactivity of these sub-
strates. HDAC8-catalyzed deacetylation of the p53 and H4
coumarin peptides has a low value of kcat/KM (10
3–
104M21s21) in comparison to enzymes that function near
diffusion-controlled limits (106–108M21s21) and a high
value for KM (320 lM, H4 peptide)
39 compared to other
HDAC isozymes ( 30 lM).42 These data suggest a simple
Michaelis–Menten kinetic model whereby substrate binding
and dissociation is rapid, and is followed by rate-limiting
deacetylation. This conclusion is bolstered by the observed
enhancement of the kcat value for deacetylation of peptides
labeled with a more reactive trifluoroacetyl group.43,44 There-
fore, substrate specificity is determined by both the affinity
of HDAC8 for a peptide substrate and the reactivity of the
enzyme–substrate complex. Assuming that the kinetic con-
stants for deacetylation of these peptides mimic the full-
length proteins, the low kcat/KM and high KM values for the
H4 and p53 peptides compared to reactivity with other iso-
zymes26,39,42 suggest that HDAC8 may not catalyze deacetyla-
tion of these sites in vivo. However, natural, full-length sub-
strates may be better optimized for efficient deacetylation to
allow for regulation of these post-translational modifications.
Cellular data implicating HDAC8-catalyzed deacetylation of
H4 and p53 in vivo is also sparse. In addition to these pro-
posed substrates, in vitro kinetic studies combined with cellu-
lar assays have yielded several promising candidates for in
vivo HDAC8 substrates (discussed further below).
There are a number of factors that must be taken into
account when parsing whether substrates are acted on by a
given enzyme in vivo. HDAC selectivity is minimally
described by the relative values of kcat/KM for deacetylation,
the relative concentrations of the HDAC isozymes, and the
concentrations of competing substrates. The relative kcat/KM
values indicate the substrate preference of an enzyme when
FIGURE 2 The Fluor-de-lys assay [Biomol].38 A. The sequence of
two HDAC8 substrates used for the Fluor-de-lys assay. B. Schematic
of the Fluor-de-lys assay, including the wavelengths used to measure
the methylcoumarin fluorophores.
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discriminating among multiple substrates.40 The majority of
enzymes have kcat/KM values of 10
5–106M21s21.45 These val-
ues are generally slower than the diffusion controlled rate
constants for substrate binding, which can be as high as 107–
108M21s21.40 Consistent with this, the kcat/KM values for the
HDAC8 homolog HDAC1 for deacetylation of the peptide,
Ac-Gly-Ala-Lys-AMC, and for the homologous enzyme, argi-
nase I, are on the order of 105 M21s21.42,46 This suggests that
similar values should be achievable with efficient HDAC8
substrates. One caveat to making conclusions from kinetic
parameters measured in in vitro experiments is that some
enzymes require an activator for optimal activity. As many
HDAC isozymes associate with large protein complexes in
vivo, it is possible that other proteins could activate the cata-
lytic activity or enhance the substrate affinity to increase the
value of kcat/KM for HDAC8 in the cell.
CANDIDATE NONHISTONE HDAC8
SUBSTRATES
One promising HDAC8 substrate is the estrogen-related re-
ceptor a (ERRa). This orphan receptor is expressed in a
number of organs, including the heart, kidney, and muscle,
where it controls processes that are essential for maintaining
energy homeostasis.47 ERRa can be acetylated at four lysines,
where these post-translational modifications inhibit DNA
binding.25 A role for HDAC8 in catalyzing the deacetylation
of ERRa was suggested by the demonstration that the acety-
lation state of ERRa was altered by simultaneous incubation
with HDAC8, the histone acetyltransferase p300 coactivator
associated factor (PCAF), and 14C-acetyl-CoA.25 Further-
more, incubation of purified acetylated-ERRa with HDAC8
enhances the affinity of ERRa for DNA, which is consistent
with HDAC8-catalyzed deacetylation of ERRa. One caveat to
these experiments is that this assay included metal chelators
and low salt, conditions where HDAC8 has limited catalytic
activity.26,48 An alternative explanation of these data is that
HDAC8 binds to ERRa to increase the DNA affinity and
decrease acetylation catalyzed by PCAF. However, addition of
the nonhomologous deacetylase, Sirt1, to these in vitro assays
also decreases acetylation of ERRa, suggesting that both
enzymes recognize ERRa as a deacetylase substrate. Finally,
RNAi-dependent decreases in cellular HDAC8 or Sirt1 levels
were accompanied by increases in ERRa acetylation in vivo.25
Taken together, these results suggest that HDAC8 catalyzes
deacetylation of ERRa in vivo. Consistent with this, the acety-
lation site [K129(ac)] in ERRa has Arg in the 21 position
(the amino acid on the N-terminal side of the acetyllysine),
and RK(ac) motifs have been demonstrated to be favorable
for HDAC8 catalysis.41 Additional analysis such as directly
measuring ERRa acetylation patterns using mass spectrome-
try in the presence and absence of HDAC inhibitors would
further validate ERRa as an in vivo substrate of HDAC8.
Another proposed HDAC8 substrate is the aberrant
inv(16) fusion protein found in a significant portion of
patients with acute myeloid leukemia.49 This fusion protein
combines the N-terminus of the transcription factor domain
core binding factor b with the C-terminus of the smooth
muscle myosin heavy chain.50 In COS7 cells, coimmunopre-
cipitation experiments demonstrated that overexpressed
HDAC8 associates with inv(16).24 Furthermore, HDAC8
colocalizes and immunoprecipitates with smooth muscle my-
osin heavy chain,51 suggesting that HDAC8 may interact
with this domain within the inv(16) fusion protein. Other
HDAC isozymes do not immunoprecipitate with inv(16)
under similar conditions, which suggests that HDAC8 may
be the main HDAC that interacts with inv(16) in vivo. The
addition of the HDAC inhibitor Trichostatin A (TSA) inhib-
its the transcriptional repression activity of inv(16),24 sug-
gesting that HDAC8 activity is important for inv(16) regula-
tion. An alternative explanation of these data is that inv(16)
is a binding partner with HDAC8 rather than a substrate, as
HDAC inhibitors have been shown to disrupt the association
of HDACs with nonsubstrate binding partners.52 The acetyla-
tion site in the core binding factor b is RSK(ac)FE.5 Peptide
library studies have demonstrated that Phe in the 11 posi-
tion is favorable for HDAC8 catalysis31,41 although Ser at the
21 position attenuates reactivity.41 While the core binding
factor b is acetylated in vivo,5 there is not yet direct evidence
that inv(16) is acetylated.53 Taken together, these data indi-
cate that inv(16) is either an HDAC8 substrate or forms a
functionally important complex with HDAC8.
A third potential in vivo HDAC8 substrate is the transcrip-
tion factor cAMP responsive element-binding protein
(CREB). Acetylation at three CREB sites (Lys91, Lys96, and
Lys136) helps to activate this protein.54 HDAC8 and CREB
overexpressed in HEK293 cells coimmunoprecipitate, dem-
onstrating that these two proteins associate. When HDAC8 is
overexpressed in cells, phosphorylation of CREB decreases,
which in turn inhibits CREB transcriptional activation.55
Likewise, treatment of cells with the HDAC inhibitor TSA
increases CREB phosphorylation levels,56 suggesting that
HDAC8 activity is important for CREB phosphorylation.
However, the addition of a broad range HDAC inhibitor
(such as TSA) decreases the activity of all metal-dependent
HDACs. As HDAC overexpression can affect a number of tar-
gets within the cell, this inhibition may indirectly affect
CREB phosphorylation. Furthermore, pulldown experiments
demonstrate that CREB can interact with a number of
HDAC isozymes,55 complicating identification of CREB as
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an HDAC8 substrate in vivo. Because of the high amino acid
identity between class I HDACs (>30%),57 overexpression
and pulldown experiments may not yield results that are rep-
resentative of in vivo situations. Therefore, these experiments
suggest, but do not confirm, a direct connection between
HDAC8 deacetylase activity, the phosphorylation status of
CREB, and the regulation of CREB activation. Alternatively,
HDACs may function as protein scaffolds to mediate the in-
hibitory interaction between CREB and PP1 phospha-
tase,55,58–60 leading to a decrease in CREB phosphorylation
and activity.
The current cellular methods for identifying substrates of
HDAC isozymes in vivo have limitations. As HDAC selectiv-
ity depends on the relative concentrations of the HDAC iso-
zymes and the concentrations of all of the acetylated lysine
substrates, overexpression of HDAC and/or HDAC substrates
can alter the normal pattern of deacetylase activity. There-
fore, experiments using overexpressed proteins can suggest
that a particular interaction occurs in vivo, but do not prove
that this contact occurs under physiological conditions.
Native pulldown experiments, which should be more repre-
sentative of physiological conditions, have thus far not been
successfully used to confirm the identity of HDAC8 sub-
strates. It is possible that the HDAC–substrate interactions
may be transient and/or weak and thus are not maintained
through the multiple washes in pulldown experiments.
Therefore, alternate techniques, such as crosslinking, may be
necessary to increase the lifetime of an HDAC–substrate
complex to allow for detection. Additionally, observation of
enhanced acetylation after deletion or knockdown of a given
isozyme does not prove that an HDAC isozyme directly cata-
lyzes deacetylation of that site. Therefore, alternative meth-
odologies need to be explored to enhance the identification
of additional HDAC8 substrates.
HDAC8 COMPLEX FORMATION
Recombinantly purified HDAC8 catalyzes deacetylation and
displays substrate selectivity in the absence of additional
protein cofactors,12,13,26–28,30–32,41,42,44,48,61 suggesting that
HDAC8 can catalyze deacetylation in vivo in the absence of a
protein complex. In contrast, the other class I HDACs,
HDAC1, 2, and 3, are observed in complexes in the cell and
their substrate specificity largely depends on the combination
of proteins incorporated into their complexes.62 HDAC1 and
2 associate with Sin3 scaffolded complexes which serve a
range of functions within the cell. The substrate specificity
and function of these HDAC isozymes can change by altering
the protein composition of the complex.63 Although HDAC8
is phylogenetically most similar to the other class I HDACs,
divergent evolution20 may have altered how HDAC8 interacts
with cofactors, possibly allowing this isozyme to function in-
dependent of other proteins. However, HDAC8 does associ-
ate with other proteins, and these interactions likely affect
the biological function and selectivity of this enzyme.
Distinguishing between HDAC8 substrates and binding
partners in the cell is currently difficult, as discussed in the
previous sections. For example, previous experiments have
provided evidence that the HDAC1/HDAC2 complex associ-
ates with both the PP1 phosphatase and CREB, leading to
decreased CREB phosphorylation.60 Because an inactive
HDAC1 mutant still affects CREB activity, the function of
the HDAC1/HDAC2 complex was proposed to colocalize
PP1 phosphatase and CREB. However, it is possible that
HDAC2 catalyzes deacetylation of CREB under these condi-
tions.60 Similarly, both PP1 and CREB coimmunoprecipitate
with HDAC8, and HDAC8 overexpression decreases CREB
activity. These data are consistent with HDAC8 either acting
as a scaffold to enhance the interaction between PP1 phos-
phatase and CREB or catalyzing deacetylation of CREB.
HDAC8 also colocalizes with a-actin, as indicated by im-
munofluorescence staining.36 This interaction was confirmed
by pulldown experiments using human smooth muscle cells,
demonstrating an endogenous association between a-actin
and HDAC8.37,51 The function of this interaction was partially
elucidated by demonstrating that siRNA knockdown of
HDAC8 in human smooth muscle cells decreased the ability of
cells to contract when exposed to a collagen lattice. Further-
more, the siRNA-treated smooth muscle culture cells were
smaller and unable to spread. These changes in cell morphol-
ogy occurred without detectable changes to a-actin acetyla-
tion,37 suggesting that HDAC8 acts as part of a complex which
modulates the cell cytoskeleton. Furthermore, the pulldown
experiments demonstrate that HDAC8 associates with the pro-
teins Hsp20, myosin heavy chain, and cofilin,51 all of which
can potentially affect actin dynamics.64,65 It is currently
unclear whether Hsp20 or cofilin are acetylated and/or sub-
strates for HDAC8. However, HDAC8 associates better with
the nonacetylated form of myosin heavy chain, suggesting that
this protein is not an HDAC8 substrate.51 Because HDAC8
enhances cell contractility and associates with three proteins
important for actin function, it is likely that HDAC8 is a com-
ponent of a complex that modulates actin dynamics.
Additional potential HDAC8 interaction partners have
been identified using a bacterial two-hybrid system.66 Two of
the 15 identified binding partners have been examined in
detail: the human Ever-Shorter Telomeres 1B (hEST1B) pro-
tein that activates telomerase activity, and HOP1, an adaptor
protein linking Hsp70 and Hsp90. The two-hybrid results
were confirmed using coimmunoprecipitation of overex-
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pressed hEST1B and HDAC8 in Hela cells. HDAC8 knock-
downs led to decreased telomerase activity through dimin-
ished levels of hEST1B. As HDAC8 activity does not affect
the promoter region regulating hEST1B, the hEST1B level is
likely not regulated by alteration in transcription. However,
hEST1B levels are increased by addition of a proteasome-de-
pendent pathway inhibitor or decreased by overexpression of
ubiquitin, which can be rescued by phosphorylated HDAC8.
These results argue that phosphorylated HDAC8 protects
hEST1B from polyubiquitination and subsequent degrada-
tion by the proteosome. The protective effects of phosphoryl-
ated HDAC8 on hEST1B levels are independent of deacety-
lase activity, remaining in the presence of the catalytically
inactive His143Ala-HDAC8 mutant, or after exposure of cells
to TSA. Therefore, HDAC8 interacts with hEST1B but deace-
tylation is not required for the functional effect. To further
explore the interaction between HDAC8 and HOP1 indicated
by the two-hybrid experiment, the association of HDAC8
with known HOP1 binding partners was investigated. The
pulldown experiments demonstrated that endogenous Hsp70
and Hsp90 coimmunoprecipitate with overexpressed
HDAC8.66 This result suggests that HDAC8, HOP1, Hsp70,
and Hsp90 form a complex. One proposed mechanism for
the effect of HDAC8 on telomerase activity suggests that the
Hsp70-HDAC8 complex protects hEST1B from ubiquitina-
tion catalyzed by the E3 ubiquitin ligase CHIP.66 This in turn
raises the levels of hEST1B and activates telomerase. Interest-
ingly, interaction of HDAC8 with the Hsp proteins may help
to elucidate the effect of HDAC8 on a-actin because Hsp90
has been proposed to modulate a-actin dynamics.67,68 Thus,
the HDAC8-HOP1-Hsp90 complex might regulate a-actin
function.
HDAC8 STRUCTURE AFFECTS SUBSTRATE
SPECIFICITY
The structure of HDAC8 yields clues about molecular recog-
nition relevant to substrate selectivity. HDAC8 is the second
smallest metal-dependent HDAC at  42 kDa, containing lit-
tle more than the catalytic domain.20,27–29 This HDAC folds
as a single a/b domain with a core eight-stranded b-sheet
surrounded by eleven a-helices (Figure 3a). The substrate
binding surface, composed of nine loops and an 11 Å tunnel
leading to the active site, is proposed to be conformationally
flexible based on the poor occupancy and varying positions
of the loop residues in crystal structures12,13,14–18 (Figure
3b). Furthermore, one crystal structure illuminates a bound
TSA molecule interacting with residues in the hydrophobic
core of HDAC815 (Figure 4). While this may simply be an ar-
tifact, the alternative binding mode suggests that the surface
of the protein can change conformation enough to allow
hydrophobic molecules to intercalate between these loops
and interact with the interior of the protein. Loops are a
common structure in promiscuous enzymes69 and examples
of proteins, such as chymotrypsin70 and carboxypeptidase
A,71 that use loops to bind a range of substrates are abundant
in nature. These loops create a number of different confor-
mations that bind ligands through a combination of induced
fit and select fit mechanisms.40,72 The varied conformations
and motifs provide a palette of binding sites to accommodate
a multiplicity of substrates. Furthermore, long-range alloste-
ric movements propagated through the loops may affect the
active site and surrounding areas, potentially altering sub-
strate preferences.
In 14 of the 21 HDAC8 crystal structures, the enzyme
crystallizes as a dimer along the substrate binding inter-
face.12,13,14–18 As HDAC8 is a monomer in solution,18 the
dimer interface may provide insight into long-range interac-
tions between HDAC8 and its in vivo substrates. To date,
substrate specificity has mainly been evaluated using peptide
substrates, therefore only short-range interactions have
emerged as HDAC8 substrate binding motifs.30–32,41 Based
on the crystal structure of bound peptides13,14 and biochemi-
FIGURE 3 HDAC8 structures. A. PDBID: 2v5w.14 Side view of
HDAC8 with bound peptide substrate. Helices are purple, sheets are
yellow, turns are white, the monovalent cations are orange, and the
active site metal is colored green. The Fluor-de-lys substrate repre-
senting the p53 sequence is colored cyan for carbon, red for oxygen,
and blue for nitrogen. B. Front view of an overlay of the 21 HDAC8
crystal structures in the PDB: PDBID: 2v5x, 2v5w, 1t69, 1t64, 1vkg,
1t67, 1w22, 3sfh, 3sff, 3mz3, 3ezt, 3fo6, 3mz4, 3mz6, 3mz7, 3ew8,
3ezp, 3f07, 3f0r, 3ewf, and 3rqd.12–18 Structural variations are espe-
cially apparent in the L1, L2, and C-terminal loops. C. A map of the
crystal structure of HDAC8 outlining the loop regions.
HDAC8 Substrates: Histones and Beyond 117
Biopolymers
cal measurements, these interactions include ring stacking,
hydrogen bonding, salt bridges, and electrostatic interactions.
Ring stacking between the Tyr100 and the methylcoumarin of
the Fluor-de-lys peptides is observed in two crystal struc-
tures.13,17 Similarly, ring stacking between aromatic amino
acids in the 11 position and Tyr100 may be important for
substrate recognition.31,41 Additionally, hydrogen bonding
between the backbone amides of the substrate and the Asp101
side chain oxygens may be important for molecular recogni-
tion.13 Salt bridges between positively charged arginines in the
substrate and negatively charged carboxylate side chain oxy-
gens, as well as general hydrophobic interactions can be seen
in the peptide–enzyme interface.13,14 Because of the limited
number of interactions, the binding affinity may be domi-
nated by a few strong contacts, as observed for the interaction
between Tyr100 of HDAC8 and the methylcoumarin moiety
of short Fluor-de-lys peptides.31,41 This pi–pi interaction ( 2
kcal/mol)73,74 is of comparable energy with other HDAC8-
peptide contacts. In contrast, binding a protein substrate could
involve many more contacts, including multiple hydrogen
bonds (0.5–1.5 kcal/mol), hydrophobic ( 1 kcal/mol), elec-
trostatic (\1 kcal/mol),40 and solvent exposed salt bridge (
1–3 kcal/mol)75 interactions. Therefore, the binding affinity
could depend on a large number of interactions that together
create a promiscuous substrate binding profile. Determinants
of substrate specificity are still being evaluated for HDACs and
further identification of binding motifs will be beneficial for
understanding the biology of these enzymes.
When the structure of HDAC8 is compared to that of the
homologous polyamine deacetylase, acetylpolyamine amido-
hydrolase (APAH),76 striking differences in loop size and
structure can be observed. These differences in the loops may
be important for substrate binding as APAH catalyzes deace-
tylation of small molecules, including acetylated spermidine,
putrescine, and spermine, while HDAC8 deacetylates macro-
molecules. In APAH, the L1 and L2 loops are much larger
and contain many more hydrophobic residues than in the
corresponding HDAC8 loops (Figures 5a and 5b), while the
C-terminal loop and helix in HDAC8 are absent in APAH.
Similarly, a comparison of the L1, L2, and C-terminal loops
of different HDACs reveals interesting variations. The L1 and
L2 loops of HDAC2,77 4,78 7,79 and 814 are more divergent in
size, structure, and number of charged residues than other
loops within these HDACs (Figures 5a and 5b). For instance,
the size and number of charges within the L1 and L2 loops
change twofold between HDAC8 and HDAC4. Comparison
of all the HDAC8 crystal structures illustrates that the L1 and
L2 loops have the most structural variability of the loops in
the proposed substrate binding surface, suggestive of a role
in ligand binding. Additionally, the L2 loop interacts with
inhibitors, suggesting that it may be important for molecular
recognition of substrates.13 The L3 loop, which lies below the
L2 loop and flanks the active site, also varies greatly in the
number of charges in the loop among HDACs 2, 4, 7, and 8,
consistent with a role in substrate or binding partner selec-
tivity. The C- and N- terminal portions of the HDACs, which
lie on the outer edge of the substrate binding surface, may
also interact with ligands. In the HDAC crystal structures,
the C-terminal loops vary in position, charge, and size and
may be responsible for long distance interactions between
HDACs and their substrates, or used for recognition of bind-
ing partners.
Along with structural studies, peptide substrates have
been useful for evaluating substrate motifs recognized by
HDAC8. Riester et al. measured the reactivity of HDAC8
with a peptide library of the sequence Ac-X-Z-K(ac)-methyl-
coumarin, where X and Z were all amino acids except for cys-
teine.30 This work indicated that HDAC8 favors Pro, Met,
Ala, Lys, Arg, Gln, Asp, Phe, and Ser at the -2 position and
aromatic (Phe, Trp, and Tyr) and hydrophobic (Ile, Met, and
Val) amino acids at the -1 position. However, the activity of
HDAC8 in these assays was low, possibly due to the inclusion
of the metal chelator EDTA in the assay. The Mrksich group
developed a mass spectrometric assay to profile the local sub-
strate specificities of HDACs.41 The reactivity of HDAC8
with a peptide array of the sequence, Ac-G-X-K(ac)-Z-G-C-
NH2 where X and Z were any amino acid other than cysteine,
showed that the most efficient substrate contains Arg and
Phe at the X and Z positions, respectively.41 However,
HDAC8 also catalyzes deacetylation of peptides containing
FIGURE 4 HDAC8 with two bound TSA molecules. PDBID:
1t64.15 In this crystal structure, one molecule of TSA binds to the
active site tunnel to coordinate the divalent metal ion (colored yel-
low) while a second TSA molecule binds nearby between the L1, L2,
and L3 loops.
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FIGURE 5 Structural variation within the structurally characterized HDACs. A. Aligned sequen-
ces of the published HDAC crystal structures.14,76–79 Highlighted in yellow are the residues that
comprise the loop regions and the putative substrate binding region. The positively charged resi-
dues are red and the negatively charged residues are green. B. Surface visualizations of the crystal
structures for HDAC2 (PDBID: 3max77), HDAC4 (PDBID: 2vqm78), HDAC7 (PDBID: 3c0y79),
HDAC8 (PDBID: 2v5w14), and APAH (PDBID: 3q9b76). Superimposed into each structure is the
Fluor-de-lys substrate (white) from the HDAC8 structure. In red are the positively charged residues
Arg and Lys, and in blue are the negatively charged residues Asp and Glu.
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the sequences: X 5 Arg/Z 5 variable and X 5 variable/Z 5
Phe. HDAC8 selectivity was further screened using a peptide
library with the following sequence: Ac-G-R-K(ac)-X-Z-C-
NH2.
31 These data demonstrated a preference for Arg or Phe
at the X position. Furthermore, when X is Phe the identity of
the Z position has only a modest effect on activity. These
results suggest that specific positions and combinations of
amino acids contribute significantly to the substrate recogni-
tion of small peptides, while other positions fine tune recog-
nition. The Mrksich group also demonstrated that an RHR
motif added to the C-terminus of peptide substrates of vary-
ing lengths enhances reactivity, demonstrating that distal
sequences can modulate HDAC8 substrate selectivity.32 Inter-
estingly, the sequences RHRK and RHKK are found in the
H4 histone tail and in p53, respectively, and hint that distal
sequences may enhance the reactivity of HDAC8 with these
substrates in cells.
Finally, the structure of the active site may also play a role
in HDAC substrate specificity. HDAC2 and 8 have well defined
11 Å channels leading to their active sites that easily accommo-
date an acetyllysine side chain, however, this tunnel is lacking
in HDAC4 and 714,77–79 where only half of the channel is appa-
rent. This modification in active site structure could suggest
that HDAC4 and 7 catalyze deacetylation of alternate sub-
strates, as proposed by Lombardi et al.76 Alternatively, these
isozymes might need substrates that complement the active
site to stabilize the binding of the acetyllysine moiety.
CATALYTIC MECHANISM AND REGULATION
OF HDAC8 ACTIVITY
The active site of HDAC8 contains a divalent metal ion coor-
dinated to two aspartate and one histidine side chains
(Asp178, Asp267, and His180) and one or two water mole-
cules. Additionally, a conserved tyrosine (Tyr306) and a pair
of conserved histidine/aspartate hydrogen bond dyads
(His142/Asp176 and His143/Asp183) are located near the
bound acetyllysine moiety (Figure 6). The enzyme is pro-
posed to catalyze hydrolysis using a metal-coordinated water
nucleophile and general acid-base catalysis (GABC) with ei-
ther one or two histidine side chains, similar to typical met-
allohydrolase mechanisms (Figure 6).13,21,80,81 The substrate
binds to HDAC8 with the catalytic metal coordinating both
the carbonyl oxygen of the acetyllysine substrate and a water
molecule. In the first step of the mechanism, His142 func-
tions as a general base to abstract a proton from the metal-
FIGURE 6 Schematic of the one base mechanism for HDAC8. Blue is the acetyl-lysine of the sub-
strate while the nucleophilic water is green and red. For clarity, equilibration of exchangeable pro-
tons with solvent is not shown.
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bound water as this nucleophile reacts with the carbonyl car-
bon to form a high energy tetrahedral intermediate. The oxy-
anion intermediate is proposed to be stabilized by coordina-
tion with the metal ion, hydrogen bonding with Tyr306, and
electrostatic interactions with positively charged groups in
the active site. Proton donation from an active site general
acid to the amine-leaving group accompanies breakdown of
the tetrahedral intermediate to form the acetate and the
deacetylated lysine products.80 In the GABC mechanism
originally proposed from the crystal structure of the homolo-
gous histone deacetylase-like protein enzyme,80 His142 and
protonated His143 are proposed to function as the general
base and general acid, respectively. In the one GABC mecha-
nism, His143 functions as both the general acid and general
base catalyst and His142 acts as an electrostatic catalyst,13,81
similar to the mechanism proposed for carboxypeptidase
A.21 Subsequent studies utilizing mutagenesis and molecular
dynamics simulations suggest a preference for the one base
mechanism.13,39,81
The HDAC8 crystal structure also contains two monovalent
cation sites,12–17 suggesting that the activity of HDAC8 may be
modulated by both the concentration and type of ions in solu-
tion. One monovalent cation site is 7 Å from the divalent cata-
lytic metal ion and is coordinated by the side chain oxygens of
Asp176 and Ser199 and the backbone carbonyl oxygens of
Asp176, Asp178, His180, and Leu200. The second site is 21 Å
from the divalent catalytic metal ion, and is ligated by two
water molecules and the backbone carbonyl oxygens of
Phe189, Thr192, Val195, and Tyr225. Initial activity measure-
ments demonstrated that the concentrations of K1 and Na1
modulate HDAC8 catalysis (biolmol unpublished). A detailed
examination demonstrated that the value of kcat/KM for
HDAC8-catalyzed deacetylation has a biphasic dependence on
the concentration of K1 and Na1 ions.48 In the absence of
monovalent ions, the activity of HDAC8 is very low; addition
of monovalent cations to Zn21-bound HDAC8 increases ac-
tivity with K1/2,act 5 14 mM for K
1. At higher K1 concentra-
tions Zn-HDAC8 activity is inhibited with K1/2,inhib 5 130
mM. Mutagenesis studies indicate a significant decrease in po-
tassium inhibition in the His142Ala and Asp176Ala/Asn
mutants, indicating that the monovalent ion site near the
active site is inhibitory. Potassium binding next to His142 has
been proposed to lower the pKa of this residue, thereby
decreasing the concentration of protonated His142 and lower-
ing catalytic activity. Similar biphasic regulation has been
measured for Na1, but activation and inhibition require a
fivefold and 10-fold higher concentration of Na1 compared to
K1, respectively.48 At the 100 mM K1 concentration within
smooth muscle cells,82 HDAC8 activity is partially inhibited
and sensitive to changes in the K1 concentration.
HDAC8 catalytic activity is enhanced by a number of
divalent metal ions, including Co21, Zn21, Ni21, and
Fe21.26 When HDAC8 is purified under aerobic conditions,
the bound metal ion is Zn21. However, recombinant
HDAC8 purified anaerobically from E. coli contains eight-
fold more iron than zinc and, consistent with this, the
recombinant HDAC8 activity in E. coli cell lysates is oxy-
gen-sensitive.26 Additionally, although HDAC8 binds Zn21
nearly 106-fold more tightly than Fe21,12 the affinities for
both metal ions are comparable to the readily exchangeable
metal concentrations estimated in living cells, suggesting
that HDAC8 can bind Fe21 and/or Zn21 in vivo. Further-
more, the identity of the bound metal ion alters the catalytic
properties of HDAC8. When catalyzing deacetylation of the
methylcoumarin-labeled p53 peptide, the kcat/KM value for
Fe21-bound HDAC8 is almost three times larger than that
of Zn21-HDAC8. Interestingly, substitution of Fe21 for
Zn21 also decreases the values of KM and KI for SAHA, sug-
gesting that Fe21 enhances ligand affinity.26 However, a
comparison of the crystal structures of the hydroxamate-
bound Fe21-HDAC8 and Zn21-HDAC8 shows no signifi-
cant differences in the active site or the rest of the protein.12
These data suggest that either binding of the hydroxamic
acid inhibitor stabilizes a common enzyme conformation,
or that the bound metal ion affects protein dynamics that
are not observable by crystallography.
Comparison of the Zn21/Fe21 metal affinities with the
cellular concentrations of those metals suggests that HDAC8
likely binds a combination of iron and zinc cofactors in eu-
karyotic cells.12 Furthermore, the cellular zinc concentration
can change dramatically upon oxidative stress83,84 and metal
toxicity,85 potentially altering the populations of Fe21-
HDAC8 and Zn21-HDAC8 based on cellular conditions.
This provides a means by which the cell can couple HDAC8
activity to cellular stresses.
A simple model for HDAC activation and inhibition
assumes that compounds, cofactors, and binding partners
equally affect the activity of HDAC8 with all substrates
(Figure 7a). An alternative to this model proposes that sub-
strate selectivity may be differentially regulated by stimuli.
For example, scaffolding activators could preferentially
enhance the binding of HDAC8 to one set of substrates
(Figure 7). Similarly, alteration of the active site metal ion or
bound monovalent ions could alter ligand specificity. For
example, Fe21-HDAC8 binds the inhibitor SAHA twofold
more tightly than Zn21-HDAC848 even though Zn21 is a
stronger Lewis acid.86 This change in binding affinity sug-
gests that the active site metal ion may contribute subtly to
the structure, dynamics, and molecular recognition of
HDACs.
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HDAC8 LOCALIZATION
Most simply, protein localization may regulate HDAC8 sub-
strate specificity by changing the effective substrate concen-
tration. HDACs have been found in a range of cellular loca-
tions. HDAC1 and 2 are exclusively nuclear, while HDAC6 is
mostly cytoplasmic, and HDACs 3, 4, 5, 6, 7, 9, 10, and 11
appear to shuttle in and out of the nucleus.87 Initially,
HDAC8 was found to have a putative nuclear localization
site and was observed in the nucleus of NIH3T327 and
HEK293 cells.28 Soon after, microscopy demonstrated that
HDAC8 localizes to both the cytoplasm and nucleus of em-
bryonic smooth muscle cells, skin fibroblasts, and NIH3T3
cells36 although there remains some skepticism about this
point. HDAC3, the closest HDAC8 human homolog,20 exists
in both the cytoplasm and nucleus, and localization has been
linked to the regulation and cellular function of this enzyme.
Whether cellular localization plays a role in HDAC8 activity
is currently unknown, as no studies have yet broached this
subject.
Determining the cell type-dependent expression of
HDAC8 may provide interesting insights about its substrate
specificity and biological function. In general, class I HDACs
are ubiquitously expressed among the various cells of an or-
ganism, whereas class II HDACs are more cell-type spe-
cific.87,88 Likewise, HDAC8 has been found in a number of
different healthy and diseased cell types [see Supporting
Information table].
HDAC8 knockouts after birth are nonlethal,89 consistent
with the ability of humans to tolerate pan-HDAC inhibitors
as an anticancer treatment.90 However, protein expression
profiles can vary significantly during development and sev-
eral HDAC knockouts are lethal during mammalian embry-
onic development.8 For example, cells lacking HDAC3 die
before embryonic day 9.5; deletion of HDAC3 leads to hyper-
activity of the nuclear receptor PPARa and problems with
embryonic gastrulation.91 Similarly, HDAC8 expression is
crucial to development, as mice lacking this enzyme die soon
after birth.89 Death is due to brain hemorrhaging caused by
defects in the development of the mouse skull resulting from
problems with neural crest patterning. These skull defects are
similar to those that occur upon overexpression of the tran-
scription factors Otx2 and Lhx1, suggesting that HDAC8 ei-
FIGURE 7 Schematic of three potential models for describing the effect of an activating effector
on HDAC activity. A. In this model, catalysis of deacetylation of each substrate is enhanced by an
equivalent factor on addition of the effector. B. In this model, catalysis of deacetylation of each sub-
strate is enhanced by a different factor upon addition of the effector. C. In this model, catalysis of
deacetylation of some substrates is activated while other substrates are inhibited by the effector.
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ther directly regulates these proteins or affects regulators of
these proteins.89 The mechanism of HDAC8 regulation of
Otx2 and Lhx1 has yet to be determined. Furthermore, since
HDAC8 knockouts are not lethal after birth,89 it is unclear
whether HDAC8 no longer regulates these proteins, this reg-




Post-translational modifications such as phosphorylation
may also regulate HDAC8 activity. A screen of three protein
kinases, casein kinase II, protein kinase A (PKA), and protein
kinase G (PKG), indicated that HDAC8 phosphorylation
could be catalyzed by both PKA and PKG.92 PKA phospho-
rylation appeared to be predominant, and this function was
authenticated in vivo by incubation of cells with the PKA in-
hibitor H-89, which lowered HDAC8 phosphorylation lev-
els.93 Based on consensus sequences, 19 potential phospho-
rylation sites were identified in HDAC8. Phosphoamino acid
analysis followed by two-dimensional thin-layer chromatog-
raphy demonstrated modification of a serine residue,93 and
based on this information, Ser39 was identified as the only
PKA phosphorylation site in the HDAC8 sequence.27,93 A
Ser39Ala HDAC8 mutant, which cannot be phosphorylated,
negates phosphorylation of HDAC8 catalyzed by PKA, con-
firming this location as the primary phosphorylation site on
HDAC8. Furthermore, phosphorylation of this site modu-
lates HDAC8 activity. The specific activity of HDAC8 puri-
fied from cells treated with forskolin, a PKA activator,
decreased by fivefold in an in vitro assay using purified his-
tones.93 Furthermore, the specific activity of Ser39Glu
HDAC8, a mutation that mimics phosphorylation, decreases
to a level comparable to that of phosphorylated HDAC8,
while the specific activity of the Ser39Ala mutant is similar to
unmodified HDAC8. To examine whether in vivo effects of
phosphorylation of HDAC8 correlate with the in vitro meas-
urements, HDAC8-transfected HeLa cells were treated with
forskolin. These cells showed increased levels of acetylated
histones H3 and H4, suggesting that the decreased deacety-
lase activity of phosphorylated HDAC8 led to increased acet-
ylation in vivo.93
Ser39 is located on the backside of the HDAC8 surface,
21Å from the catalytic metal ion12–17 (Figure 8). Nonetheless,
phosphorylation has the potential to affect the subcellular
localization, protein–protein interactions, allosteric effects,
and HDAC8 activity via conformational changes that propa-
gate to the active site or enzyme–substrate interface. Ser39
lies near the junction with the L1 loop12–17 that has been
implicated in substrate recognition, and therefore phospho-
rylation at that position may alter enzyme–substrate interac-
tions. The Ser39 residue is located in a pocket on the enzyme
surface surrounded by hydrophobic and acidic residues sug-
gesting that phosphorylation of Ser39 could induce a struc-
tural perturbation due to the altered charge.15 Ser39 also
contacts the conserved Arg37 residue which is proposed to
be important for gating an acetate release channel in
HDAC861 (Figure 8). The Arg37Ala mutation decreases the
kcat/KM value for Co
21-HDAC8-catalyzed deacetylation of
the Fluor-de-lys substrate (R-H-K(ac)-K(ac)-methylcou-
marin) by 530-fold.61 Based on the proximity of Ser39 to
Arg37, phosphorylation at this position may similarly affect
HDAC8 activity.
Phosphorylation may also regulate HDAC8 through the
modulation of protein–protein interactions. In the bacterial
two-hybrid assay that identified 15 HDAC8-interacting pro-
teins,66 expression of PKA was necessary for the pulldown of
six of these identified proteins, and this suggests that these
proteins interact solely with phosphoHDAC8. Two of these
interactions, those between HDAC8 and hEST1B and
between HDAC8 and Hsp70, were further observed by coim-
munoprecipitation, showing that treatment of cells with for-
skolin led to increased amounts of phosphorylated HDAC8
and increased interactions.66 These data strongly suggest that
FIGURE 8 Phosphorylation of Ser39 may affect the active site
structure and/or reactivity of HDAC8. PDBID: 2v5w.14 This struc-
ture shows that phosphorylation of Ser39 (red) may be able to per-
turb the position and/or electrostatic environment of Arg37 (or-
ange) and in turn, affect the active site residues (yellow). Blue is the
Fluor-de-lys substrate and green is the active site metal.
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HDAC8 phosphorylation regulates HDAC8 complex forma-
tion. Similarly, phosphorylation of HDAC1 and HDAC2 reg-
ulates association of these proteins with complexes such as
mSin3A, RbAp48, and CoREST.92,94 Phosphorylation-de-
pendent complex formation may also regulate the cellular
localization of HDAC8. Fluorescence microscopy of myome-
trial cells shows that HDAC8 and phosphoHDAC8 both
localize primarily to the cytosol while cell fractionation data
suggest that phosphoHDAC8 has increased association with
the cytoskeleton compared to HDAC8 in this cell type.51
HDAC4, HDAC5, and HDAC7 have been proposed to utilize
nuclear-cytoplasmic shuttling mechanisms involving phos-
phorylation-dependent binding to 14-3-3 proteins for regu-
lating their subcellular localization, and a similar mechanism
may regulate HDAC8 localization.95–98
The Ser39 site is an interesting location for phosphoryla-
tion among HDACs. Ser39 is not conserved among class I
HDACs; the residue in the corresponding position of other
class I HDACs is arginine in HDAC1 and 2, and alanine in
HDAC3. Also, HDAC8 and HDAC5 contain the only phos-
phorylation sites that are located within the HDAC catalytic
domain.99–101 Additionally, HDAC8 is the only isozyme
phosphorylated by PKA.101 In general, the effect of phospho-
rylation on the activity of other class I isozymes HDAC1 and
HDAC2 is ambiguous and/or contradictory.92,94,102,103 For
example, phosphorylation of HDAC1 had little to no effect
on deacetylase activity using a synthetic histone H4 pep-
tide102,103 but activity on isolated histones decreased using
mutants that could not be phosphorylated.94 Therefore,
HDAC8 may be the best isozyme for examining the role of
phosphorylation in regulating acetylation.
Many HDACs undergo additional post-translational mod-
ifications including acetylation, ubiquitination, and sumoyla-
tion,100 but additional modifications of HDAC8 have not yet
been demonstrated. HDAC8 has a consensus motif for glyco-
sylation at Asn136 that could be modified;27,93 however the
NetNGlyc 1.0 server does not predict N-glycosylation of this
site due to the lack of a signal peptide.104 Acetylation has
been observed for HDAC1 at multiple sites, and one of the
acetylated residues is conserved in HDAC8. Two of the
HDAC1 sites are located in the deacetylase domain and four
sites are near the C-terminus; acetylation of these sites inhib-
its HDAC1 deacetylase activity toward histones in vitro and
corepressor function in vivo.105 The two sites in the deacety-
lase domain, Lys218 and Lys220, are located near the activat-
ing monovalent cation binding site, so decreased activity
from acetylation of these residues may arise from alteration
of monovalent cation binding.105 Sequence alignment by
Cobalt indicates that the Lys218 position in HDAC1 is con-
served in the corresponding Lys221 position in HDAC8
(http:www.ncbi.nlm.nih.gov/tools/cobalt/). As this monova-
lent site activates HDAC8 allosterically,48 it is feasible that
HDAC8 activity could be regulated by modification at this
location. However, no modifications at this site have yet been
observed and post-translational modifications of HDAC8
need to be further examined.
CONCLUDING REMARKS
Because of the abundance and vital function of acetylation
within the cell, enzymes that catalyze acetylation and deacetyla-
tion are regulated in a multitude of ways and on a number of
time scales. One mechanism of regulating HDAC activity is
changing the substrate preferences for these enzymes, which in
turn affects cellular processes. These regulatory mechanisms
may allow the cell to finely tune the substrate preference for
many HDACs simultaneously by allowing the same stimuli to
differentially alter the activity of each HDAC isozyme. Under-
standing the interplay between various stimuli and HDAC reg-
ulation will give us tremendous insight into the inner workings
of cellular processes and the mechanisms of disease formation.
Even though HDAC8 has been extensively studied, it is hum-
bling to know the vast amounts of information that have yet to
be determined regarding the cohort of HDAC8 substrates and
binding partners, localization in the cell, and regulatory mech-
anisms. Therefore, even for the best-characterized HDAC, there
are likely many factors that affect substrate recognition that
have not yet been discovered. The dissection of these factors in
the future will be tremendously important for understanding
not only the cellular function of HDACs, but also cellular regu-
lation by post-translational modifications.
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